Gileads Sciences news and Full Year 2018 Financial Results

Alleen voor leden beschikbaar, wordt daarom gratis lid!

Algemeen advies 05/02/2019 07:37
Gilead Sciences Announces Fourth Quarter and Full Year 2018 Financial Results
- Fourth Quarter Product Sales of $5.7 billion -
- Full Year 2018 Product Sales of $21.7 billion -
- Full Year 2018 Diluted EPS of $4.17 per share -
- Full Year 2018 Non-GAAP Diluted EPS of $6.67 per share -

FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 4, 2019-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2018. Total revenues for the fourth quarter of 2018 were $5.8 billion compared to $5.9 billion for the same period in 2017. Net income for the fourth quarter of 2018 was $3 million, or $0.00 earnings per diluted share, compared to net loss of $3.9 billion, or $2.96 loss per diluted share for the same period in 2017. The earnings per share for the fourth quarter of 2018 included an unfavorable impact of $0.99 per diluted share from an impairment and a non-cash tax charge related to intangible assets acquired from Kite Pharma, Inc. (Kite). Non-GAAP net income for the fourth quarter of 2018 was $1.9 billion, or $1.44 per diluted share, compared to $2.3 billion, or $1.78 per diluted share for the same period in 2017.

Full year 2018 total revenues were $22.1 billion, compared to $26.1 billion for 2017. Net income for 2018 was $5.5 billion, or $4.17 per diluted share, compared to $4.6 billion, or $3.51 per diluted share for 2017. Non-GAAP net income for 2018 was $8.7 billion, or $6.67 per diluted share, compared to $11.7 billion, or $8.84 per diluted share for 2017.

Three Months Ended Twelve Months Ended
December 31, December 31,
(In millions, except per share amounts) 2018 2017 2018 2017
Product sales $ 5,681 $ 5,837 $ 21,677 $ 25,662
Royalty, contract and other revenues 114 112 450 445
Total revenues $ 5,795 $ 5,949 $ 22,127 $ 26,107

Net income (loss) attributable to Gilead $ 3 $ (3,865 ) $ 5,455 $ 4,628
Non-GAAP net income $ 1,873 $ 2,343 $ 8,728 $ 11,654

Diluted earnings (loss) per share $ — $ (2.96 ) $ 4.17 $ 3.51
Non-GAAP diluted earnings per share $ 1.44 $ 1.78 $ 6.67 $ 8.84

Note:

Non-GAAP financial information excludes acquisition-related, up-front collaboration, stock-based compensation and other expenses, fair value adjustments of marketable equity securities and discrete tax charges or benefits associated with changes in tax related laws and guidelines. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 8 through 11.



Product Sales

Total product sales for the fourth quarter of 2018 were $5.7 billion, compared to $5.8 billion for the same period in 2017. Product sales for the fourth quarter of 2018 were $4.5 billion in the United States, $813 million in Europe and $398 million in other locations. Product sales for the fourth quarter of 2017 were $4.1 billion in the United States, $1.1 billion in Europe and $553 million in other locations.

Total product sales in 2018 were $21.7 billion, compared to $25.7 billion in 2017. For 2018, product sales were $16.2 billion in the United States, $3.7 billion in Europe and $1.8 billion in other locations. For 2017, product sales were $18.1 billion in the United States, $5.0 billion in Europe and $2.6 billion in other locations.


see & read more on
https://www.gilead.com/news-and-press/press-room/press-releases/2019/2/gilead-sciences-announces-fourth-quarter-and-full-year-2018-financial-results

Gilead Sciences Announces 11 Percent Increase in First Quarter 2019 Dividend
FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 4, 2019-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 11% in the company’s quarterly cash dividend, beginning in the first quarter of 2019. The increase will result in a quarterly dividend of $0.63 per share of common stock. The dividend is payable on March 28, 2019, to stockholders of record at the close of business on March 15, 2019. Future dividends will be subject to Board approval.



Beperkte weergave !
Leden hebben toegang tot meer informatie! Omdat u nog geen lid bent of niet staat ingelogd, ziet u nu een beperktere pagina. Wordt daarom GRATIS Lid of login met uw wachtwoord


Copyrights © 2000 by XEA.nl all rights reserved
Niets mag zonder toestemming van de redactie worden gekopieerd, linken naar deze pagina is wel toegestaan.


Copyrights © DEBELEGGERSADVISEUR.NL